fibrin and Prostatic-Hyperplasia

To explore mechanisms of coagulation activation in adenocarcinoma of the prostate, the occurrence and distribution of components of coagulation and fibrinolysis pathways in situ were studied by means of immunohistochemical techniques applied to frozen sections of fresh malignant and benign hyperplastic prostatic tissue obtained at transurethral resection. Fibrinogen was distributed throughout the perivascular and tumor connective tissue in both malignant and benign disease but was not present in adjacent areas of normal prostate. Antibodies specific for fibrin and D-dimer crosslink sites stained vascular endothelium focally in both malignant and benign tissues. Both neoplastic cells and benign hyperplastic glandular epithelial cells stained weakly and in a patchy distribution for tissue factor and focally for low-molecular-weight urokinase-type plasminogen activator. Focal staining of vascular endothelium was also observed for tissue plasminogen activator and plasmin-antiplasmin complex neoantigen. By contrast, no tissue staining was observed for factor VII, factor X, factor XIII "a" subunit, high-molecular-weight urokinase-type plasminogen activator, plasminogen activator inhibitors 1 to 3, protein C, and protein S. Thus, the similarity in findings between benign hyperplastic and neoplastic prostate tissue, the lack of either an intact tumor cell-associated coagulation pathway or fibrin formation, and the presence of fibrin on vascular endothelium are consistent with the concept that coagulation activation in prostatic cancer may not be due to a direct effect of the tumor cells on the clotting mechanism. Rather, such activation may be induced by a soluble tumor product that activates procoagulant activity on certain host (for example, vascular endothelial) cells. These findings, together with the lack of effect of warfarin anticoagulation on the clinical course of patients with prostatic cancer, contrast with findings in certain other tumor types and suggest that coagulation activation may not contribute to progression of adenocarcinoma of the prostate.

Topics: Antibodies, Monoclonal; Endothelium, Vascular; Fibrin; Fibrinogen; Humans; Male; Molecular Weight; Plasminogen Activators; Prostatic Hyperplasia; Prostatic Neoplasms; Survival Rate; Thromboplastin; Warfarin

The plasminogen activator content of the extracts of excise prostate cancers (25 specimens) was determined with an azocasein assay and found to be on the average 1.7 times higher than that of extracts of excised prostate benign hyperplasias (29 specimens). Both groups contained the same average percentage of human urokinase type activator (approximately 45%) as determined by the inhibition of activity when anti-human urokinase antibody was included in the assay system. The two types of activators were partially purified and found to have distinctly different properties. The most striking difference was the large augmentation of activity o the non-urokinase enzyme in fibrinolysis. The implications of an enhanced fibrinolysis relative to azocaseinolysis (or other) is discussed, particularly with respect to its importance in the quantitation and characterization of activators by different investigators. Highly purified urokinase-like activator was found to be similar to commercial urokinase preparation with respect to molecular weight, isoelectric point, inhibition by the antibody, and inhibition by placenta inhibitor.

Topics: Fibrin; Humans; Hyperplasia; Male; Plasminogen Activators; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Urokinase-Type Plasminogen Activator

On the basis of literature and own experience is reported on principle and practice of a new method of tissue glueing with fibron gluten. The fibrin gluten is a first-class possibility also for blood-stanching. In the transvesical adenomectomy the author used for blood-stanching is the prostatic loge with good success fibrin gluten. Thus is became possible to perform a simultaneous "miniheparin"-thrombosis prevention without having the risk of a secondary hemorrhage.

Topics: Fibrin; Hemostasis, Surgical; Humans; Male; Prostatectomy; Prostatic Hyperplasia; Tissue Adhesives; Wound Healing

In the transvesical adenomectomy the author used human fibrin adhesive for stopping a bleeding in the prostatic lodge. Thus an essential reduction of the blood loss in the postoperative time was achieved. The difference between the patients who were treated with an adhesive and control patients is significant.

Topics: Fibrin; Hemostasis, Surgical; Humans; Male; Prostatectomy; Prostatic Hyperplasia; Tissue Adhesives

Topics: Aminocaproates; Animals; Caseins; Cattle; Fibrin; Fibrinogen; Fibrinolysin; Fibrinolytic Agents; Glycine max; Humans; Iodine Isotopes; Male; Peptide Hydrolases; Plasminogen; Prostate; Prostatic Hyperplasia; Serum Globulins; Streptokinase; Trypsin; Trypsin Inhibitors

Topics: Aged; Amputation, Surgical; Blood Coagulation; Blood Coagulation Tests; Child; Dilatation; Disseminated Intravascular Coagulation; Fibrin; Genital Diseases, Male; Humans; Male; Methods; Penile Diseases; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Testicular Diseases; Urethral Diseases; Urethral Stricture; Urologic Diseases

Topics: Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Drug Therapy; Fibrin; Fibrinogen; Fibrinolysin; Fibrinolysis; Humans; Male; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Surgical Procedures, Operative; Trypsin Inhibitors; Urologic Diseases